# Myseum.AI, Inc.: financial statements, quarterly

MYSE · Nasdaq · CIK 1648960 · [Communication](/sectors/communication.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/myse.md) · [Financials](/companies/myse/financials.md) · [Filings](/companies/myse/filings.md) · [Insiders](/companies/myse/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/myse/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [0.2](/filings/0001213900-24-098452.md) | [0.2 d](/filings/0001013762-25-004290.md) | [0.1](/filings/0001213900-25-044159.md) | [0.2](/filings/0001213900-25-076607.md) | [0.1](/filings/0001213900-25-110045.md) | [0.1 d](/filings/0001213900-26-036485.md) | [0.1](/filings/0001213900-26-057778.md) | [0.1](/filings/0001213900-26-090015.md) | [0.3](/filings/0001213900-25-110045.md) | [0.1 d](/filings/0001213900-26-036485.md) | [0.1](/filings/0001213900-26-057778.md) | [0.0](/filings/0001213900-26-090015.md) |
| Research and development | $k | [380](/filings/0001213900-24-098452.md) | [351 d](/filings/0001013762-25-004290.md) | [234](/filings/0001213900-25-044159.md) | [226](/filings/0001213900-25-076607.md) | [363](/filings/0001213900-25-110045.md) | [(657) d](/filings/0001213900-26-036485.md) | [6.0](/filings/0001213900-25-044159.md) | [5.0](/filings/0001213900-25-076607.md) | [0.0 d](/filings/0001213900-25-110045.md) | not reported | not reported | not reported |
| Operating income | $k | [(2,542)](/filings/0001213900-24-098452.md) | [(1,493) d](/filings/0001013762-25-004290.md) | [(1,663)](/filings/0001213900-25-044159.md) | [(1,267)](/filings/0001213900-25-076607.md) | [(1,238)](/filings/0001213900-25-110045.md) | [952 d](/filings/0001213900-26-036485.md) | [(1,434)](/filings/0001213900-26-057778.md) | [(1,194)](/filings/0001213900-26-090015.md) | [(1,281)](/filings/0001213900-25-110045.md) | [(1,142) d](/filings/0001213900-26-036485.md) | [(1,685)](/filings/0001213900-26-057778.md) | [(2,152)](/filings/0001213900-26-090015.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(2,365)](/filings/0001213900-24-098452.md) | [(1,354) d](/filings/0001013762-25-004290.md) | [(1,138)](/filings/0001213900-25-044159.md) | [(983)](/filings/0001213900-25-076607.md) | [(1,272)](/filings/0001213900-25-110045.md) | [(846) d](/filings/0001213900-26-036485.md) | [(1,473)](/filings/0001213900-26-057778.md) | [(1,217)](/filings/0001213900-26-090015.md) | [(1,201)](/filings/0001213900-25-110045.md) | [1,284 d](/filings/0001213900-26-036485.md) | [(2,862)](/filings/0001213900-26-057778.md) | [(3,050)](/filings/0001213900-26-090015.md) |
| Diluted EPS | $ per share | [(1.13)](/filings/0001213900-24-098452.md) | not reported | [(0.41)](/filings/0001213900-25-044159.md) | [(0.33)](/filings/0001213900-25-076607.md) | [(0.42)](/filings/0001213900-25-110045.md) | not reported | [(0.36)](/filings/0001213900-26-057778.md) | [(0.29)](/filings/0001213900-26-090015.md) | [(0.28)](/filings/0001213900-25-110045.md) | not reported | [(0.67)](/filings/0001213900-26-057778.md) | [(0.61)](/filings/0001213900-26-090015.md) |
| Basic EPS | $ per share | [(1.13)](/filings/0001213900-24-098452.md) | not reported | [(0.41)](/filings/0001213900-25-044159.md) | [(0.33)](/filings/0001213900-25-076607.md) | [(0.42)](/filings/0001213900-25-110045.md) | not reported | [(0.36)](/filings/0001213900-26-057778.md) | [(0.29)](/filings/0001213900-26-090015.md) | [(0.28)](/filings/0001213900-25-110045.md) | not reported | [(0.67)](/filings/0001213900-26-057778.md) | [(0.61)](/filings/0001213900-26-090015.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.7](/filings/0001213900-23-086183.md) | [1.0](/filings/0001013762-25-004290.md) | [0.2](/filings/0001213900-24-042992.md) | [0.6](/filings/0001213900-24-069051.md) | [0.6](/filings/0001213900-24-098452.md) | [0.8](/filings/0001213900-26-036485.md) | [1.3](/filings/0001213900-25-044159.md) | [0.4](/filings/0001213900-25-076607.md) | [0.5](/filings/0001213900-25-110045.md) | [0.7](/filings/0001213900-26-090015.md) | [0.8](/filings/0001213900-26-057778.md) | [1.9](/filings/0001213900-26-090015.md) |
| Current assets | $m | [7.8](/filings/0001213900-23-086183.md) | [6.4](/filings/0001013762-25-004290.md) | [6.3](/filings/0001213900-24-042992.md) | [5.4](/filings/0001213900-24-069051.md) | [4.8](/filings/0001213900-24-098452.md) | [4.3](/filings/0001213900-26-036485.md) | [7.2](/filings/0001213900-25-044159.md) | [5.8](/filings/0001213900-25-076607.md) | [5.1](/filings/0001213900-25-110045.md) | [4.0](/filings/0001213900-26-090015.md) | [2.9](/filings/0001213900-26-057778.md) | [4.2](/filings/0001213900-26-090015.md) |
| Total assets | $m | [8.0](/filings/0001213900-23-086183.md) | [6.5](/filings/0001013762-25-004290.md) | [6.4](/filings/0001213900-24-042992.md) | [5.4](/filings/0001213900-24-069051.md) | [4.8](/filings/0001213900-24-098452.md) | [5.4](/filings/0001213900-26-036485.md) | [8.5](/filings/0001213900-25-044159.md) | [7.4](/filings/0001213900-25-076607.md) | [6.8](/filings/0001213900-25-110045.md) | [7.2](/filings/0001213900-26-090015.md) | [4.9](/filings/0001213900-26-057778.md) | [5.3](/filings/0001213900-26-090015.md) |
| Current liabilities | $m | [0.5](/filings/0001213900-23-086183.md) | [0.4](/filings/0001013762-25-004290.md) | [0.4](/filings/0001213900-24-042992.md) | [0.4](/filings/0001213900-24-069051.md) | [0.5](/filings/0001213900-24-098452.md) | [0.6](/filings/0001213900-26-036485.md) | [0.7](/filings/0001213900-25-044159.md) | [0.6](/filings/0001213900-25-076607.md) | [0.9](/filings/0001213900-25-110045.md) | [0.9](/filings/0001213900-26-090015.md) | [0.9](/filings/0001213900-26-057778.md) | [0.8](/filings/0001213900-26-090015.md) |
| Total liabilities | $m | [0.5](/filings/0001213900-23-086183.md) | [0.4](/filings/0001013762-25-004290.md) | [0.4](/filings/0001213900-24-042992.md) | [0.4](/filings/0001213900-24-069051.md) | [0.5](/filings/0001213900-24-098452.md) | [0.6](/filings/0001213900-26-036485.md) | [0.7](/filings/0001213900-25-044159.md) | [0.8](/filings/0001213900-25-076607.md) | [1.1](/filings/0001213900-25-110045.md) | [1.1](/filings/0001213900-26-090015.md) | [1.1](/filings/0001213900-26-057778.md) | [0.9](/filings/0001213900-26-090015.md) |
| Shareholders' equity | $m | [7.5](/filings/0001213900-23-086183.md) | [6.1](/filings/0001013762-25-004290.md) | [6.8](/filings/0001213900-24-042992.md) | [6.1](/filings/0001213900-24-069051.md) | [7.1](/filings/0001213900-24-098452.md) | [6.9](/filings/0001213900-26-036485.md) | [10.3](/filings/0001213900-25-044159.md) | [9.2](/filings/0001213900-25-076607.md) | [8.3](/filings/0001213900-25-110045.md) | [6.1](/filings/0001213900-26-090015.md) | [3.9](/filings/0001213900-26-057778.md) | [4.4](/filings/0001213900-26-090015.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,979) d](/filings/0001213900-24-098452.md) | [(1,370) d](/filings/0001013762-25-004290.md) | [(1,477)](/filings/0001213900-25-044159.md) | [(1,073) d](/filings/0001213900-25-076607.md) | [(957) d](/filings/0001213900-25-110045.md) | [(1,304) d](/filings/0001213900-26-036485.md) | [(1,190)](/filings/0001213900-26-057778.md) | [(1,292) d](/filings/0001213900-26-090015.md) | [(1,033) d](/filings/0001213900-25-110045.md) | [(752) d](/filings/0001213900-26-036485.md) | [(1,251)](/filings/0001213900-26-057778.md) | [(1,512) d](/filings/0001213900-26-090015.md) |
| Capital expenditure | $k | [17.3 d](/filings/0001213900-24-098452.md) | [0.0 d](/filings/0001013762-25-004290.md) | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001213900-25-110045.md) | [0.0 d](/filings/0001213900-26-036485.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [2,060](/filings/0001213900-23-086183.md) | [2,061](/filings/0001213900-24-042992.md) | [2,074](/filings/0001213900-24-069051.md) | [2,089](/filings/0001213900-24-098452.md) | [2,806](/filings/0001213900-25-044159.md) | [3,009](/filings/0001213900-25-076607.md) | [3,009](/filings/0001213900-25-110045.md) | [4,089](/filings/0001213900-26-057778.md) | [4,209](/filings/0001213900-26-090015.md) | [4,222](/filings/0001213900-25-110045.md) | [4,282](/filings/0001213900-26-057778.md) | [4,981](/filings/0001213900-26-090015.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 5,196,430 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001213900-26-090015.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.